Antibodies as Drugs: Immunological Scaffolds as Therapeutics
joint with Tumor Immunology: Multidisciplinary Science Driving Combination Therapy
Organizer(s): Pablo Umaña, Mark X. Sliwkowski and Martin J. GlennieDate: February 08 - 13, 2015
Location: Fairmont Banff Springs, Banff, AB, Canada
Monoclonal antibodies are now an established class of drugs in oncology and inflammation. In addition, exciting progress has been recently made on next-generation, engineered therapeutic antibodies and alternative immunological scaffolds, with the first examples from this class being recently approved by the FDA and EMA. This Keystone Symposia meeting will review progress in this area, including lessons learned in the clinic and how this can be applied to new targets and drug candidates. The meeting will cover major areas of activity including: 1) Increasing antibody potency via antibody engineering, better engaging immune effector cells, and improvements in targeted delivery of effectors via fusion proteins and via conjugation of cytotoxic drugs; 2) Applying alternative targeting approaches to increase the therapeutic window, such as pre-targeting and site-specific antibody unmasking; 3) Novel antibodies in areas outside of oncology, including infectious diseases, neurology and chronic inflammation; 4) Engineering antibodies and scaffolds for alternative delivery routes and improved disposition; 5) Clinical progress with multi-specific antibodies; and 6) Recent advances in (i) addressing difficult targets such as GPCRs and ion channels, (ii) alternative immunological scaffolds, and (iii) novel antibody library technologies. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “Tumor Immunology - Multidisciplinary Science Driving Combination Therapy,” which will be co-located with this meeting.
Scholarship Deadline: October 9 2014
Discounted Abstract Deadline: October 9 2014
Abstract Deadline: November 12 2014
Discounted Registration Deadline: December 9 2014
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
BioNTech RNA Pharmaceuticals GmbH
Celldex Therapeutics, Inc.
Heptares Therapeutics Ltd
Janssen R&D: Pharmaceutical Companies of Johnson & Johnson
Molecular Partners AG
Regeneron Pharmaceuticals, Inc.
Roche Diagnostics GmbH
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI116024-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.